Shares of ThermoGenesis Holdings, Inc. (NASDAQ:THMO) dropped 0.4% during mid-day trading on Monday . The stock traded as low as $2.30 and last traded at $2.38. Approximately 59,025 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 690,035 shares. The stock had previously closed at $2.39.
Separately, Zacks Investment Research upgraded shares of ThermoGenesis from a “sell” rating to a “hold” rating in a research note on Thursday, August 12th.
The company has a market capitalization of $27.52 million, a price-to-earnings ratio of -1.92 and a beta of 3.23. The firm’s 50 day moving average price is $2.35 and its two-hundred day moving average price is $2.55. The company has a current ratio of 1.35, a quick ratio of 0.86 and a debt-to-equity ratio of 0.08.
Several institutional investors have recently added to or reduced their stakes in THMO. State Street Corp bought a new stake in shares of ThermoGenesis during the 2nd quarter worth about $45,000. Geode Capital Management LLC boosted its holdings in shares of ThermoGenesis by 55.5% during the 2nd quarter. Geode Capital Management LLC now owns 34,861 shares of the company’s stock worth $92,000 after buying an additional 12,449 shares during the period. Vanguard Group Inc. boosted its holdings in shares of ThermoGenesis by 276.4% during the 2nd quarter. Vanguard Group Inc. now owns 259,610 shares of the company’s stock worth $688,000 after buying an additional 190,645 shares during the period. XTX Topco Ltd bought a new stake in shares of ThermoGenesis during the 2nd quarter worth about $36,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of ThermoGenesis during the 2nd quarter worth about $59,000. Institutional investors own 3.80% of the company’s stock.
About ThermoGenesis (NASDAQ:THMO)
ThermoGenesis Holdings, Inc engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. It operates through the Device and Clinical Development segment. The Device segment includes the development and commercialization of automated technologies for cell-based therapeutics and bioprocessing.
Featured Article: Cash Flow Analysis in Stock Selection
Receive News & Ratings for ThermoGenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ThermoGenesis and related companies with MarketBeat.com's FREE daily email newsletter.